Vaginal Estrogen Therapy for Urinary Incontinence in Postmenopausal Women
Introduction to Vaginal Estrogen Therapy
- The American College of Physicians recommends vaginal estrogen formulations, such as tablets or ovules, for the treatment of stress urinary incontinence in postmenopausal women, with strong guideline support 1
- Vaginal estrogen improves continence and stress urinary incontinence in postmenopausal women, with moderate-quality evidence 1
Critical Distinction: Route of Administration Matters
- Vaginal estrogen formulations, such as tablets, ovules, or cream, improve continence and stress urinary incontinence in postmenopausal women, whereas transdermal estrogen patches worsen urinary incontinence 1
- The difference in outcomes is due to the local benefits of vaginal estrogen, including restoration of vaginal pH and lactobacillus colonization, without significantly increasing serum estrogen levels 2
Safety Profile and Common Concerns
- Vaginal estrogen has minimal systemic absorption and does not require progesterone co-administration, even in women with an intact uterus, with moderate-quality evidence 2
- Large prospective cohort studies have found no increased risk of endometrial cancer, stroke, venous thromboembolism, invasive breast cancer, or colorectal cancer with vaginal estrogen 2
- Vaginal estrogen does not increase the risk of breast cancer recurrence in women using it for urogenital symptoms, with moderate-quality evidence 2
Type-Specific Recommendations
- For stress urinary incontinence, vaginal estrogen tablets or ovules are appropriate, and systemic pharmacologic therapy is contraindicated, with strong guideline support 1
- For urgency urinary incontinence, vaginal estrogen represents a reasonable alternative approach if antimuscarinic agents have failed or caused intolerable side effects, with moderate-quality evidence 1
- For mixed urinary incontinence, vaginal estrogen combined with pelvic floor muscle training and bladder training addresses both stress and urgency components, with moderate-quality evidence 1
Evidence Quality Assessment
- The recommendation for vaginal estrogen is based on strong guideline support from the American College of Physicians for vaginal formulations in stress incontinence, and moderate-quality evidence showing vaginal estrogen prevents recurrent UTI and improves incontinence in postmenopausal women 1, 2
Vaginal Estrogen Therapy for Urinary Incontinence in Postmenopausal Women
Introduction to Vaginal Estrogen Therapy
- Vaginal estrogen tablets and ovules are effective for treating urinary incontinence in postmenopausal women, with vaginal estrogen tablets showing significant improvement in continence compared to placebo (number needed to treat of 5) 3, 4, 5
Recommended Formulations and Dosing
- Vaginal estrogen tablets have demonstrated effectiveness in improving urinary incontinence symptoms 3, 4
- Vaginal ovules (suppositories) have also shown improvement in UI compared to placebo 3, 4
Combination Therapy Considerations
- Low-quality evidence shows that combining intravaginal estriol with pelvic floor muscle training (PFMT) is more effective at achieving continence than intravaginal estriol alone (number needed to treat of 1) 3, 4, 5
- PFMT plus bladder training improved UI more than pharmacologic treatment alone 3
Important Clinical Considerations
- Transdermal estrogen patches are NOT recommended for UI as they were associated with worsened urinary incontinence symptoms 3, 4, 6
- Estradiol implants did not improve UI compared with placebo 3, 4